This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead

California-based TCG Crossover Management reported a buy of 300,000 shares in Amylyx Pharmaceuticals (NASDAQ:AMLX) during the third quarter, increasing its position by approximately $46.8 million, according to an SEC filing on Friday.According to a filing submitted to the Securities and Exchange Commission on Friday, TCG Crossover Management increased its stake in Amylyx Pharmaceuticals (NASDAQ:AMLX) by purchasing an additional 300,000 shares during the third quarter. The fund’s position in the company grew to 6.2 million shares with a reported market value of $84.9 million as of September 30.The fund's AMLX position now represents 4.2% of its $2 billion in 13F reportable AUM.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool